Intech Investment Management LLC Reduces Holdings in Insulet Corporation $PODD

Posted by Geri Gentry on May 31st, 2026

Intech Investment Management LLC decreased its position in Insulet Corporation (NASDAQ:PODD – Free Report) by 48.4% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 25,214 shares of the medical instruments supplier’s stock after selling 23,655 shares during the period. Intech Investment Management LLC’s holdings in Insulet were worth $7,167,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Glenmede Investment Management LP boosted its position in Insulet by 1.6% in the third quarter. Glenmede Investment Management LP now owns 2,292 shares of the medical instruments supplier’s stock valued at $708,000 after buying an additional 35 shares during the last quarter. Curi Capital LLC boosted its position in Insulet by 0.8% in the second quarter. Curi Capital LLC now owns 4,346 shares of the medical instruments supplier’s stock valued at $1,365,000 after buying an additional 36 shares during the last quarter. WINTON GROUP Ltd boosted its position in Insulet by 0.9% in the third quarter. WINTON GROUP Ltd now owns 4,086 shares of the medical instruments supplier’s stock valued at $1,261,000 after buying an additional 37 shares during the last quarter. Camarda Financial Advisors LLC boosted its position in Insulet by 0.5% in the second quarter. Camarda Financial Advisors LLC now owns 7,332 shares of the medical instruments supplier’s stock valued at $2,304,000 after buying an additional 40 shares during the last quarter. Finally, Larson Financial Group LLC boosted its position in Insulet by 114.6% in the fourth quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier’s stock valued at $25,000 after buying an additional 47 shares during the last quarter.

Insulet Trading Up 1.6%

Shares of NASDAQ:PODD opened at $144.94 on Friday. Insulet Corporation has a 1 year low of $140.63 and a 1 year high of $354.88. The firm has a market capitalization of $10.04 billion, a price-to-earnings ratio of 33.71, a price-to-earnings-growth ratio of 1.15 and a beta of 1.20. The company has a debt-to-equity ratio of 0.71, a current ratio of 2.49 and a quick ratio of 1.81. The business’s 50 day moving average price is $183.55 and its 200-day moving average price is $245.30.

Insulet (NASDAQ:PODD – Get Free Report) last announced its earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.19 by $0.23. Insulet had a return on equity of 26.87% and a net margin of 10.44%.The firm had revenue of $761.70 million for the quarter, compared to analyst estimates of $729.89 million. During the same quarter last year, the firm posted $1.02 EPS. The business’s revenue was up 33.9% on a year-over-year basis. Insulet has set its FY 2026 guidance at 6.210- EPS. On average, equities research analysts forecast that Insulet Corporation will post 6.44 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on PODD shares. Stifel Nicolaus lowered their price objective on Insulet from $350.00 to $250.00 in a research report on Thursday, May 7th. William Blair started coverage on Insulet in a research report on Wednesday, May 20th. They issued an “outperform” rating on the stock. Jefferies Financial Group lowered their price objective on Insulet from $400.00 to $360.00 in a research report on Thursday, May 7th. BTIG Research lowered their price objective on Insulet from $260.00 to $235.00 and set a “buy” rating on the stock in a research report on Tuesday. Finally, Royal Bank Of Canada restated an “outperform” rating and issued a $280.00 price objective on shares of Insulet in a research report on Wednesday. Twenty-one research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $252.04.

Get Our Latest Research Report on PODD

Insulet Company Profile

(Free Report)

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.

Intech Investment Management LLC Reduces Holdings in Insulet Corporation $PODD

Insulet Trading Up 1.6%

Analyst Upgrades and Downgrades

Insulet Company Profile

See Also

You might be interested in: